# Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

> **NCT04883125** · PHASE2 · COMPLETED · sponsor: **Mansoura University** · enrollment: 90 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia, BCR-ABL Positive
- CML, Chronic Phase

## Interventions

- **DRUG:** Pioglitazone 15mg

## Key facts

- **NCT ID:** NCT04883125
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-04-15
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883125, "Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04883125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*